Last reviewed · How we verify
WVE-210201
At a glance
| Generic name | WVE-210201 |
|---|---|
| Sponsor | Wave Life Sciences Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (PHASE2, PHASE3)
- Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |